AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22240389 — intervention group
Group type: COMPARATOR
Intervention: Tablet containing 8 mg dexamethasone
Number of subjects: 0
Study 19962411 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive head up tilt (HUT)
Number of subjects: 15
Study 19962411 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental arithmetic (MA)
Number of subjects: 15
Study 19962411 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined MA+HUT
Number of subjects: 15
Study 19962411 — intervention group
Group type: COMPARATOR
Intervention: HUT
Number of subjects: 15
Study 19962411 — intervention group
Group type: COMPARATOR
Intervention: MA+HUT
Number of subjects: 15
Study 17483542 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 10 mg and placebo
Number of subjects: 34
Study 17483542 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg and Candesartan 16 mg
Number of subjects: 34
Study 17483542 — intervention group
Group type: COMPARATOR
Intervention: Candesartan 16 mg and placebo
Number of subjects: 34
Study 17483542 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Ramipril 10 mg and Candesartan 16 mg)
Number of subjects: 34
Study 17483542 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril therapy
Number of subjects: 34
Study 17483542 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 34
Study 17483542 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan therapy
Number of subjects: 34
Study 16305585 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐193884 (200 mg, oral)
Number of subjects: 0
Study 16305585 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS‐193884 (50 nmol min(‐1), intra-arterial)
Number of subjects: 0
Study 12195542 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interventions
Number of subjects: 216
Study 12195542 — intervention group
Group type: COMPARATOR
Intervention: Control group (no interventions)
Number of subjects: 216
Study 9794714 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive treatment (placebo-controlled randomized trial)
Number of subjects: 631
Study 7657739 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotrophins (1.5 to 2.5 ampoules per day, decreasing by 0.5 ampoules/day)
Number of subjects: 82
Study 7657739 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotrophins
Number of subjects: 82
Study 2706175 — intervention group
Group type: EXPERIMENTAL
Intervention: Orogastric tube followed by 30 ml of sodium citrate 0.3 mol litre‐1
Number of subjects: 183
Study 2706175 — intervention group
Group type: COMPARATOR
Intervention: 30 ml of sodium citrate 0.3 mol litre‐1
Number of subjects: 183
Study 2706175 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 50 mg i.v. before operation, in addition to sodium citrate
Number of subjects: 183
Study 811573 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfanilamide and sulfathiazole cones
Number of subjects: 94
Study 811573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 811573 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 94
Study 31600833 — intervention group
Group type: EXPERIMENTAL
Intervention: bFGF related decapeptide solution plus Tacrolimus 0.1% ointment (M + T)
Number of subjects: 94
Study 31600833 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus 0.1% ointment (T)
Number of subjects: 94
Study 28274323 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education sessions about menopause (2 sessions)
Number of subjects: 131
Study 28274323 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 131
Study 24914429 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based oral health intervention programme with dental hygienists working 4 hours weekly for two years, including fluoride varnish treatments every 6 months.
Number of subjects: 534
Study 24914429 — intervention group
Group type: COMPARATOR
Intervention: Control group with no intervention.
Number of subjects: 534
Study 24160382 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral triamcinolone acetonide 0.5 mg
Number of subjects: 126
Study 24160382 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral triamcinolone acetonide 1.0 mg
Number of subjects: 126
Study 24160382 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral triamcinolone acetonide 2.0 mg
Number of subjects: 126
Study 24160382 — intervention group
Group type: COMPARATOR
Intervention: Control group (no triamcinolone acetonide)
Number of subjects: 126
Study 21792066 — intervention group
Group type: EXPERIMENTAL
Intervention: Full mitochondrial DNA (mtDNA) sequence analysis
Number of subjects: 423
Study 21792066 — intervention group
Group type: EXPERIMENTAL
Intervention: African mtDNA haplogroup
Number of subjects: 423
Study 18728037 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorylcholine coating (PC)
Number of subjects: 120
Study 18728037 — intervention group
Group type: COMPARATOR
Intervention: Non-coated circuits
Number of subjects: 120
Study 17699190 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet
Number of subjects: 1676
Study 17699190 — intervention group
Group type: COMPARATOR
Intervention: Usual-protein diet
Number of subjects: 1676
Study 17699190 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-protein diet with dietary supplements (study B)
Number of subjects: 1676
Study 17699190 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (study A)
Number of subjects: 1676
Study 15729207 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal cytoreductive surgery by well trained specialists
Number of subjects: 190000
Study 15729207 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 190000
Study 11369159 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (median first dose 75 microg/h, median final dose 100 microg/h)
Number of subjects: 73
Study 11369159 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (for > or =3 months until death)
Number of subjects: 73
Study 9164988 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg zinc gluconate/d for 15 days
Number of subjects: 0
Study 9164988 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8333158 — intervention group
Group type: EXPERIMENTAL
Intervention: Test stimulus at 10 c/deg with a 10 c/deg masker
Number of subjects: 0
Study 8333158 — intervention group
Group type: EXPERIMENTAL
Intervention: Test stimuli at 2 c/deg and 8 c/deg with the same masker
Number of subjects: 0
Study 3653532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg twice daily for 1 week
Number of subjects: 6
Study 3653532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29429464 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DRD4 genotype
Number of subjects: 164
Study 29429464 — intervention group
Group type: EXPERIMENTAL
Intervention: DRD4 exon III 48bp VNTR
Number of subjects: 164
Study 29429464 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's rejection/denial
Number of subjects: 164
Study 29429464 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex
Number of subjects: 164
Study 29429464 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between sex and DRD4 exon III 48bp VNTR
Number of subjects: 164
Study 29429464 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between DRD4 exon III 48bp VNTR and mother's rejection/denial
Number of subjects: 164
Study 27712733 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ipsilateral ulnar compression during radial artery hemostasis
Number of subjects: 3000
Study 27712733 — intervention group
Group type: COMPARATOR
Intervention: Standard patent hemostasis protocol
Number of subjects: 3000
Study 27712733 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ipsilateral ulnar compression
Number of subjects: 3000
Study 24744272 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous warfarin therapy (group 2)
Number of subjects: 1584
Study 24744272 — intervention group
Group type: COMPARATOR
Intervention: Warfarin discontinuation (group 1)
Number of subjects: 1584
Study 24473583 — intervention group
Group type: EXPERIMENTAL
Intervention: Dense cranial electroacupuncture stimulation (DCEAS)
Number of subjects: 0
Study 24473583 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 0
Study 21209504 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of school teachers, training of journalists, interactive discussions with school children, communication through local media
Number of subjects: 288
Study 18536787 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with carboplatin and paclitaxel (CbP)
Number of subjects: 0
Study 18536787 — intervention group
Group type: COMPARATOR
Intervention: Standard platinum-based doublet (without bevacizumab)
Number of subjects: 0
Study 16202177 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/d for 6 weeks then 10 mg/d for 6 weeks
Number of subjects: 13
Study 16202177 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil for patients with clinically significant depressive symptoms
Number of subjects: 13
Study 16202177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 12647275 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/d)
Number of subjects: 8
Study 12647275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10772527 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine 50 mg/m2 orally every 12 hr
Number of subjects: 77
Study 8868268 — intervention group
Group type: EXPERIMENTAL
Intervention: High resistance (HR group: 4 sets, 8 reps, 8RM loading)
Number of subjects: 22
Study 8868268 — intervention group
Group type: COMPARATOR
Intervention: Low resistance (LR group: 4 sets, 24 reps, 24RM loading)
Number of subjects: 22
Study 8868268 — intervention group
Group type: COMPARATOR
Intervention: Loaded kicking movements (LK group: 4 sets, 16 reps, 16RM loading)
Number of subjects: 22
Study 8868268 — intervention group
Group type: COMPARATOR
Intervention: Control group (CO group)
Number of subjects: 22
Study 1299489 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin/mineral supplementation
Number of subjects: 82
Study 1299489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 6438048 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg enoxacin as a single oral dose
Number of subjects: 22
Study 6438048 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg enoxacin given twice with an interval of 4 hours
Number of subjects: 22
Study 31806612 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent eye and hand movement training
Number of subjects: 30
Study 31806612 — intervention group
Group type: COMPARATOR
Intervention: Standard visual scanning therapy (VST)
Number of subjects: 30
Study 28390970 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5mA anodal tDCS over left dorsolateral prefrontal cortex
Number of subjects: 20
Study 28390970 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 29736463 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised functional electrical stimulation (FES) cycling
Number of subjects: 16
Study 29736463 — intervention group
Group type: COMPARATOR
Intervention: Passive cycling (Control)
Number of subjects: 16
Study 24866478 — intervention group
Group type: EXPERIMENTAL
Intervention: OC000459 25 mg once daily
Number of subjects: 125
Study 24866478 — intervention group
Group type: EXPERIMENTAL
Intervention: OC000459 pooled dose groups
Number of subjects: 125
Study 24866478 — intervention group
Group type: EXPERIMENTAL
Intervention: OC000459 in atopic eosinophilic subjects
Number of subjects: 125
Study 24866478 — intervention group
Group type: EXPERIMENTAL
Intervention: OC000459 in subjects aged ≤40 years
Number of subjects: 125
Study 24866478 — intervention group
Group type: EXPERIMENTAL
Intervention: OC000459
Number of subjects: 125
Study 24866478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 22881465 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fluence multiple pass diode laser
Number of subjects: 30
Study 22881465 — intervention group
Group type: COMPARATOR
Intervention: High fluence single pass IPL
Number of subjects: 30
Study 18488223 — intervention group
Group type: EXPERIMENTAL
Intervention: Newcastle disease virus (NDV) infected autologous tumour cell vaccine (ATV‐NDV), administered in six doses after liver resection.
Number of subjects: 50
Study 18488223 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 50
Study 17244231 — intervention group
Group type: EXPERIMENTAL
Intervention: Full coverage hard maxillary stabilization splints
Number of subjects: 0
Study 17244231 — intervention group
Group type: COMPARATOR
Intervention: Maintaining or increasing contact with the splint
Number of subjects: 0
Study 16255987 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 157
Study 16255987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ap‐237
Number of subjects: 157
Study 16255987 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular morphine
Number of subjects: 157
Study 16255987 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 157
Study 16255987 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 157
Study 16255987 — intervention group
Group type: EXPERIMENTAL
Intervention: Stilamin (250 microg/h)
Number of subjects: 157
Study 16255987 — intervention group
Group type: EXPERIMENTAL
Intervention: Stilamin (500 microg/h)
Number of subjects: 157
Study 16255987 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandostatin
Number of subjects: 157
Study 16255987 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 157
Study 16255987 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN)
Number of subjects: 157
Study 16255987 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaerythritol tetranitrate (PTN)
Number of subjects: 157
Study 16255987 — intervention group
Group type: EXPERIMENTAL
Intervention: Associated application of ISDN and GTN
Number of subjects: 157
Study 16255987 — intervention group
Group type: EXPERIMENTAL
Intervention: Associated application with PTN
Number of subjects: 157
Study 16255987 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisodamine or atropine
Number of subjects: 157
Study 16255987 — intervention group
Group type: EXPERIMENTAL
Intervention: Buscopan
Number of subjects: 157
Study 11851659 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) biopsy using dye‐guided or gamma probe‐guided method, combined with step sectioning, haematoxylin and eosin staining, and immunohistochemistry.
Number of subjects: 0
Study 11851659 — intervention group
Group type: COMPARATOR
Intervention: Routine axillary lymph node dissection (ALND)
Number of subjects: 0
Study 10461843 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine vaginal douching
Number of subjects: 1130
Study 10461843 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline vaginal douching
Number of subjects: 1130
Study 7588340 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond 2 Light Cure Dental Adhesive
Number of subjects: 32
Study 7588340 — intervention group
Group type: COMPARATOR
Intervention: Tubulitec Primer and Liner
Number of subjects: 32
Study 1979900 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin hydrochloride 1.5 mg/day for the first week and 3.0 mg/day for two weeks (Group E)
Number of subjects: 323
Study 1979900 — intervention group
Group type: COMPARATOR
Intervention: Bethanechol chloride 15 mg three times daily for three weeks (Group B)
Number of subjects: 323
Study 1979900 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 323
Study 1979900 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin hydrochloride (Group E)
Number of subjects: 323
Study 457886 — intervention group
Group type: EXPERIMENTAL
Intervention: Ego-involvement condition (manipulated through instructions, data identification method, and E interaction with a confederate)
Number of subjects: 48
Study 457886 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-involvement condition (manipulated through instructions, data identification method, and E interaction with a confederate)
Number of subjects: 48
Study 31592824 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanosecond pulsed electric field (nsPEF) treatment
Number of subjects: 72
Study 31558473 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 417
Study 31558473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study 31558473 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated baseline VEGFA
Number of subjects: 417
Study 31558473 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated baseline thyroglobulin
Number of subjects: 417
Study 31558473 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined VEGFA/thyroglobulin signatures
Number of subjects: 417
Study 31558473 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF mutations
Number of subjects: 417
Study 31558473 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS mutations
Number of subjects: 417
Study 28385353 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed triple therapy (extrafine beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide)
Number of subjects: 2691
Study 28385353 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium
Number of subjects: 2691
Study 28385353 — intervention group
Group type: EXPERIMENTAL
Intervention: Open triple therapy (BDP/FF plus tiotropium)
Number of subjects: 2691
Study 28385353 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed triple therapy
Number of subjects: 2691
Study 28385353 — intervention group
Group type: EXPERIMENTAL
Intervention: Open triple therapy
Number of subjects: 2691
Study 25972054 — intervention group
Group type: EXPERIMENTAL
Intervention: TEE-guided early direct current cardioversion (DCC)
Number of subjects: 126
Study 25972054 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with dabigatran-etexilat for 3 weeks followed by DCC
Number of subjects: 126
Study 24229084 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-rich linseed oil mixture (17 g/d)
Number of subjects: 38
Study 24229084 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (17 g/d)
Number of subjects: 38
Study 24229084 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 38
Study 24229084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheek cell FA
Number of subjects: 38
Study 21253725 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of tranexamic acid (TXA) 2000 mg/20 ml
Number of subjects: 100
Study 21253725 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 100
Study 19101222 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxus stent
Number of subjects: 2736
Study 19101222 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent
Number of subjects: 2736
Study 17192509 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 8
Study 17192509 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan
Number of subjects: 8
Study 14709369 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial remnant-like particle (RLP) metabolism in the IR group
Number of subjects: 52
Study 14709369 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial RLP-C concentration changes during the fat-loading test in the IR group
Number of subjects: 52
Study 14709369 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of HOMA-R with fasting and postprandial triglyceride and RLP-C
Number of subjects: 52
Study 14709369 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial RLP-C concentration as a predictor of HOMA-R
Number of subjects: 52
Study 11468543 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (30 mg once daily)
Number of subjects: 154
Study 11468543 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril (10 mg once daily)
Number of subjects: 154
Study 9721802 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose azathioprine (5 mg/kg/day, adjusted to maintain 6-TGN levels between 100 and 200 pmol/8 x 10(8) RBCs)
Number of subjects: 360
Study 9721802 — intervention group
Group type: COMPARATOR
Intervention: Low-dose azathioprine (3 mg/kg on day 0, then 2 mg/kg/day the first week and 1 mg/kg/day thereafter)
Number of subjects: 360
Study 7988502 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromides (BR) as add‐on therapy
Number of subjects: 22
Study 2574054 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg acrivastine
Number of subjects: 103
Study 2574054 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg acrivastine
Number of subjects: 103
Study 2574054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 789445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Ritodrine
Number of subjects: 26
Study 789445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31348498 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 730
Study 31348498 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice break timing
Number of subjects: 730
Study 31348498 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone levels at voice break
Number of subjects: 730
Study 31348498 — intervention group
Group type: EXPERIMENTAL
Intervention: LH levels at voice break
Number of subjects: 730
Study 31348498 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-testicular volume at voice break
Number of subjects: 730
Study 31348498 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with other milestones
Number of subjects: 730
Study 31348498 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-specific BMI association
Number of subjects: 730
Study 28935921 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (Lactobacillus casei strain Shirota‐fermented milk)
Number of subjects: 70
Study 28935921 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 70
Study 25902552 — intervention group
Group type: EXPERIMENTAL
Intervention: High CHO diet (70% CHO)
Number of subjects: 19